Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Eric Hughes, Teva's EVP of Global R&D & Chief Medical Officer, will present at the BofA Securities Health Care Conference ...
Teva Pharmaceutical Industries (NYSE:TEVA) reported first-quarter 2026 results that management said reflect continued ...
Teva Pharmaceutical Industries (NYSE:TEVA) reported first-quarter 2026 results that management said reflected continued ...
Blackstone committed $400 million to fund development of Teva's promising autoimmune disease drug duvakitug. This deal ...
The Federal Circuit recently clarified its written description jurisprudence concerning claims directed to methods of using a ...
Teva Pharmaceuticals has struck a deal to buy Emalex Biosciences for $700 million | Teva Pharmaceuticals has struck a deal to ...
In the days when that healthcare segment was relatively limited, Teva ruled its niche. But success attracts competition, and ...
5d
Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution
For an accessible version of this Press Release, please visit Q1 2026 revenues of ~$4.0 billion increased by 2% in U.S.
By Siddhi Mahatole April 29 (Reuters) - Teva Pharmaceutical beat first-quarter profit estimates on Wednesday as growth in its ...
On April 29, 2026, Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced entering into a definitive agreement to ...
Teva (TEVA) stock jumps as the company exceeds forecasts with Q1 2026 financials. However, it cut its 2026 earnings outlook ...
Teva’s largest in a decade — “makes sense” given the synergies between Emalex and the pharmaceutical giant’s neurology ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results